Biomarin Pharmaceutical Inc. (BMRN)
BMRN (NASDAQ:Drugs)
$57.21
-1.10
-1.89%
Today's Range: 57.16 - 58.60 |
BMRN Avg Daily Volume: 1,418,000
| Last Update: 06/19/13 - 4:00 PM EDT |
| Volume: 652,642 |
| YTD Performance: 18.52%
|
| Open: $58.30 |
| Previous Close: $58.31 |
| 52 Week Range: $35.99 -
$71.56 |
| Oustanding Shares: 139,010,175 |
| Market Cap: 8,105,683,304 |
6-Month Chart
TheStreet Ratings Grade for BMRN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
14 |
12 |
12 |
13 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
3 |
4 |
4 |
4 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.39 |
1.53 |
1.53 |
1.50 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
-55.53 |
|
| Price Earnings Comparisons: |
| BMRN |
Sector Avg. |
S&P 500 |
| -55.53 |
0.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-5.16%
|
55.08%
|
189.38%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
13.50 |
0.54 |
0.15 |
| Net Income |
0.00 |
233.32 |
0.00 |
| EPS |
0.00 |
0.00 |
0.00 |
| Earnings for BMRN: |
| EBITDA |
-0.06B |
| Revenue |
0.50B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$-0.28 |
$-0.32 |
$-1.28 |
$-0.75 |
| Number of Analysts |
11 |
11 |
15 |
13 |
| High Estimate |
$-0.23 |
$-0.24 |
$-1.00 |
$-0.20 |
| Low Estimate |
$-0.33 |
$-0.37 |
$-1.43 |
$-1.47 |
| Prior Year |
$-0.27 |
$-0.04 |
$-0.95 |
$-1.28 |
| Growth Rate (Year over Year) |
-3.70% |
-690.91% |
-34.46% |
41.34% |
Jun 03, 2013 | 11:25 AM EDT
May 31, 2013 | 7:59 AM EDT
BMRN price target was raised to $79 as anti-cancer drug BMN-673 was included in the model, said Citigroup.
May 31, 2013 | 7:22 AM EDT
BMRN was initiated with a Neutral rating, Credit Suisse said. Valuation call, based on a $68 price target.
Apr 02, 2013 | 11:58 AM EDT
| Feb 25, 2013 | 8:30 AM EST
Stocks that defy correction and those ripe for correction.
| Feb 19, 2013 | 10:18 AM EST
The slow, steady push higher continues.
By
Adam Feuerstein
Feb 07, 2013 | 11:38 AM EST
| Feb 05, 2013 | 10:53 AM EST
It's the bulls' turn to shine.
Jan 22, 2013 | 8:28 AM EST
BMRN was upgraded from Hold to Buy, Stifel Nicolaus said. $67 price target. New products should drive growth and the company is a poten...
By
Adam Feuerstein and Gregg Greenberg
Jan 04, 2013 | 5:00 AM EST
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
